PDCD1 and cancer: Following this clue, several studies demonstrated that targeted depletion of CCR8+ Tregs with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) strategy induced potent anticancer response and synergized with anti-PD-1 treatment in several murine cancer models [9–13].